Foreverland Food | $6,956,279 | (Mar 24, 2026)
Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Certified by Founder
Lodge
ErVimmune
start up
- 21/01/2026
- Series A
- $19,917,795
Targeting shared unconventional tumor antigens in cancer immunotherapy
- Industry Biotechnology Research
- Website https://ervimmune.com/
- LinkedIn https://www.linkedin.com/company/ervimmune/
Related People
Stéphane DEPILFounder
France -
Onco-hematologist at Centre Léon Bérard and leader of the team "Antigen presentation, T cell and Cancer" at Cancer Research Center of Lyon. Over 20 years of experience in oncology research and drug development both in academia and pharma/biotech companies as former SVP R&D and CMO at Cellectis, CEO at Netris Pharma and Head of OncologyR&D at Servier.Founder and board member of ErVimmune, a biotech company developing cancer vaccines and T cell therapies targeting non-conventional tumor epitopes.
Hamilton AI | $7,500,000 | (Mar 24, 2026)
Flourish Care | $5,700,000 | (Mar 24, 2026)
eternal.ag | $9,271,160 | (Mar 24, 2026)
SPARK Microsystems | $12,364,525 | (Mar 24, 2026)
JAAQ | $17,416,100 | (Mar 24, 2026)
CisLunar Industries | $2,600,000 | (Mar 24, 2026)